Compare Costco Wholesale Corporation (COST) vs Zoetis Inc (ZTS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Costco Wholesale Corporation vs Zoetis Inc — how do they compare? Costco Wholesale Corporation trades at $946.92 (market cap $420.05B), while Zoetis Inc trades at $74.77 (market cap $30.20B). The key difference: Costco Wholesale Corporation is far larger — about 13.9× Zoetis Inc's market cap, and Zoetis Inc pays the higher dividend (2.9%). Which is the better fit depends on your goals — on Pluang, investors hold Costco Wholesale Corporation for 133 Days and Zoetis Inc for 70 Days on average.
| COST | ZTS | |
|---|---|---|
Market Cap | $420.05B | $30.20B |
Volume | 2,087,565 | 6,175,327 |
Sector | Consumer Staples | Health |
52-Week High | $1.09K | $147.53 |
52-Week Low | $849.63 | $69.09 |
Typical Hold Time | 133 Days | 70 Days |
Enterprise Value | $407.33B | $37.76B |
Dividend Yield | 0.62% | 2.9% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Costco (COST) trades at $947.92, up 0.6% on the day, near its pivot point of $947 with strong analyst consensus. The stock shows bullish moving averages but overbought RSI signals. Recent March sales surged 11.3% year-over-year to $28.41 billion (Costco report, April 8, 2026), while Q2 2026 EPS beat expectations. Valuation remains elevated with a P/E of 45.66, supported by robust membership fee growth and expansion.
Outlook is positive given consistent revenue growth and high renewal rates post-fee hike, but risks include premium valuation sensitivity and competitive pressures. The consensus price target of $1,100 implies ~16% upside, with institutional buying underscoring confidence. Key catalysts are Q3 2026 earnings and sustained comp sales momentum.
Zoetis (ZTS) trades at $74.77, up 4.5% with strong profitability metrics including 71.67% gross margins and 27.69% net income margin. The stock shows mixed technical signals with bullish oscillators but bearish moving averages, trading near resistance at $75. Recent earnings show beats in Q4 2025 and Q2 2026 but a miss in Q1 2026, with Q3 2026 results pending. The company maintains robust cash flow generation despite competitive pressures in the U.S. companion animal market.
Zoetis presents a compelling value opportunity with a P/E of 11.92 below industry averages, though near-term headwinds from pet care weakness and competition persist. Analyst consensus targets $87.33 with no sell ratings, suggesting 17% upside potential. Key risks include ongoing margin pressure and market share challenges, but strong international growth and dividend sustainability support long-term bullish thesis.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Costco Wholesale Corporation
The leading warehouse club, Costco has 815 stores worldwide (at the end of fiscal 2021), with most sales derived in the United States (72%) and Canada (14%). It sells memberships that allow customers to shop in its warehouses, which feature low prices on a limited product assortment. Costco mainly caters to individual shoppers, but roughly 20% of paid members carry business memberships. Food and sundries accounted for 40% of fiscal 2021 sales, with non-food merchandise 29%, warehouse ancillary and other businesses (such as fuel and pharmacy) nearly 17%, and fresh food 14%. Costco's warehouses average around 146,000 square feet
Read more on COST →About Zoetis Inc
Zoetis sells anti-infectives, vaccines, parasiticides, diagnostics, and other health products for animals. The firm earns slightly less than half of total revenue from production animals (cattle, pigs, poultry, and so on), and more than half from companion animal (dogs, horses, cats) products make up the other half. Its U.S. business is heavily skewed toward companion animals, while its international business is slightly skewed toward production animals. The firm has the largest market share in the industry and was previously Pfizer's animal health unit.
Read more on ZTS →
